Defunct Company
Total Trials
7
As Lead Sponsor
As Collaborator
0
Total Enrollment
386
NCT05019794
Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations
Phase: Phase 2
Role: Lead Sponsor
Start: May 13, 2020
Completion: Dec 30, 2023
NCT05135871
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
Phase: Phase 1
Start: Oct 31, 2021
Completion: Feb 28, 2022
NCT05174416
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
Phase: Phase 3
Start: Jan 4, 2022
Completion: Jul 22, 2024
NCT05621525
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
Start: Oct 18, 2022
Completion: Mar 29, 2024
NCT05629390
Trial to Evaluate the Efficacy and Safety of TP-03, LIBRA Study
Start: Oct 23, 2022
Completion: Apr 2, 2024
NCT06032936
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
Start: Jul 27, 2023
NCT06206278
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma
Start: Oct 19, 2023
Completion: May 31, 2024